

Jason A Efstathiou

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7658008/jason-a-efstathiou-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

5,678
citations

34
h-index

72
g-index

182
ext. papers

7,616
ext. citations

5.5
avg, IF

5.8
L-index

#	Paper	IF	Citations
166	Bladder cancer. <i>Lancet, The</i> , 2016 , 388, 2796-2810	40	669
165	Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. <i>European Urology</i> , 2012 , 61, 705-11	10.2	264
164	Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. <i>European Urology</i> , 2020 , 77, 38-52	10.2	258
163	Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3801-9	2.2	245
162	Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. <i>Journal of Clinical Oncology</i> , 2009 , 27, 92-9	2.2	201
161	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3648-3654	2.2	200
160	Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. <i>European Urology</i> , 2014 , 66, 120-37	10.2	190
159	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). <i>European Urology</i> , 2018 , 74, 294-306	10.2	176
158	Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 329-354	7.3	159
157	Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>European Urology</i> , 2017 , 71, 952-960	10.2	153
156	Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. <i>European Urology</i> , 2008 , 54, 816-23	10.2	148
155	Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4055-61	2.2	146
154	Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 225-35	5.5	101
153	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Practical Radiation Oncology</i> , 2018 , 8, 354-360	2.8	90
152	HIV Infection and Survival Among Women With Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3749-3757	2.2	87
151	Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base. <i>European Urology</i> , 2015 , 68, 768-74	10.2	82
150	Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 1028-1036	4	82

149	Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. <i>European Urology</i> , 2017 , 71, 729-737	10.2	81
148	328. Kaposi Sarcoma in High Population ART Utilization Setting: An Observational Study in Botswana. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S174-S175	1	78
147	Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. <i>Cancer</i> , 2007 , 110, 2691-9	6.4	77
146	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. <i>Cancer Discovery</i> , 2018 , 8, 288-303	24.4	76
145	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1213-1224	7.3	73
144	Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	67
143	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2019 , 76, 59-68	10.2	63
142	Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 1081-9	4	62
141	Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 1048-56	4	57
140	EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. <i>Cancer Research</i> , 2014 , 74, 2825-34	10.1	50
139	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. <i>JAMA Oncology</i> , 2018 , 4, e175230	13.4	49
138	Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 61-8	7.3	49
137	DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. <i>Seminars in Radiation Oncology</i> , 2015 , 25, 237-50	5.5	48
136	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. <i>Lancet Oncology</i> , 2018 , 19, e683-e695	21.7	44
135	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3908-3920	12.9	42
134	Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 287-295	4	38
133	Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. <i>World Journal of Urology</i> , 2016 , 34, 97-103	4	37
132	Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 454-464	4	34

131	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 1046-1053	4	34
130	PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. <i>Oncogene</i> , 2018 , 37, 2793-2805	9.2	32
129	Establishing and Delivering Quality Radiation Therapy in Resource-Constrained Settings: The Story of Botswana. <i>Journal of Clinical Oncology</i> , 2016 , 34, 27-35	2.2	32
128	SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 61-83	4	31
127	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. <i>Journal of Urology</i> , 2019 , 201, 528-534	2.5	31
126	Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 78-86	4	31
125	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 174-185	4	31
124	Developing a national radiation oncology registry: From acorns to oaks. <i>Practical Radiation Oncology</i> , 2012 , 2, 10-7	2.8	30
123	Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. <i>Cancer</i> , 2016 , 122, 78-83	6.4	29
122	What is the best way to radiate the prostate in 2016?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 59-68	2.8	28
121	Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs. <i>Frontiers in Oncology</i> , 2015 , 5, 239	5.3	28
120	Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. <i>European Urology</i> , 2016 , 69, 204-10	10.2	26
119	Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. <i>Molecular Cancer Research</i> , 2015 , 13, 713-20	6.6	25
118	Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 618-23	4	25
117	Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 468-75	4	25
116	Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. <i>Radiotherapy and Oncology</i> , 2012 , 103, 12-7	5.3	25
115	Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2009 , 15, 312-8	2.2	24
114	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020 , 6, 735-743	13.4	23

113	Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2018 , 199, 407-415	2.5	23
112	Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 78-85	4	23
111	Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 78.e1-78.e12	2.8	23
110	Long-term impact of a faculty mentoring program in academic medicine. <i>PLoS ONE</i> , 2018 , 13, e0207634	3.7	23
109	Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. <i>Cancer Medicine</i> , 2017 , 6, 1827-1836	4.8	22
108	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 165-202	1	22
107	Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. <i>Journal of Oncology Practice</i> , 2013 , 9, e90-5	3.1	22
106	Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. <i>Oncologist</i> , 2016 , 21, 731-8	5.7	22
105	Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 23-31.e3	3.3	21
104	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. <i>Cancer</i> , 2016 , 122, 1505-12	6.4	19
103	Beyond a moonshot: insurance coverage for proton therapy. <i>Lancet Oncology, The</i> , 2016 , 17, 559-61	21.7	19
102	Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2020 , 3, e208221	10.4	18
101	Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 1302-8	4	18
100	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. <i>European Urology</i> , 2018 , 74, 99-106	10.2	18
99	Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. <i>European Urology Oncology</i> , 2019 , 2, 79-87	6.7	17
98	Bladder-sparing approaches to invasive disease. <i>World Journal of Urology</i> , 2006 , 24, 517-29	4	17
97	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 544-552	13.4	17
96	Multicriteria plan optimization in the hands of physicians: a pilot study in prostate cancer and brain tumors. <i>Radiation Oncology</i> , 2017 , 12, 168	4.2	16

95	Association Between Declared Hurricane Disasters and Survival of Patients With Lung Cancer Undergoing Radiation Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 269-277	17.4	16
94	The Rationale for Post-Operative Radiation in Localized Bladder Cancer. <i>Bladder Cancer</i> , 2017 , 3, 19-30	1	16
93	Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer?. <i>Bladder Cancer</i> , 2015 , 1, 15-27	1	16
92	Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. <i>Practical Radiation Oncology</i> , 2017 , 7, e125-e133	2.8	14
91	Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. <i>Cancer Treatment Reviews</i> , 2018 , 70, 88-97	14.4	14
90	Weight gain on androgen deprivation therapy: which patients are at highest risk?. <i>Urology</i> , 2014 , 83, 1316-21	16.2	14
89	Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 509-521	6.2	13
88	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020 , 78, 43-59	9.2	13
87	Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 1188-1193	4	12
86	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2021 , 81, 95-95	10.2	12
85	Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. <i>Acta Oncologica</i> , 2017 , 56, 575-581	3.2	11
84	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 53-64	2.8	11
83	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. <i>European Urology Oncology</i> , 2020 , 3, 420-423	6.7	11
82	Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?. <i>Translational Andrology and Urology</i> , 2016 , 5, 702-710	2.3	11
81	Proton therapy for prostate cancer: A review of the rationale, evidence, and current state. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 628-636	2.8	11
80	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. <i>Journal of Urology</i> , 2018 ,	2.5	11
79	MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 197-206	4	10
78	National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e167-72	3.3	10

77	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 213-218	3.3	10
76	Cervical brachytherapy exchange: steps toward oncology capacity building in Botswana. <i>Oncologist</i> , 2014 , 19, e1-2	5.7	10
75	Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012. <i>Practical Radiation Oncology</i> , 2016 , 6, e249-e258	2.8	10
74	The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 10.e7-10.e14	2.8	9
73	Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. <i>Journal of Urology</i> , 2019 , 201, 721-727	2.5	9
72	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. <i>BJU International</i> , 2016 , 118, 279-85	5.6	9
71	The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016 , 2, 480-487	5.1	9
70	Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 430.e1-7	2.8	8
69	Bladder preservation strategies. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 289-300, ix	3.1	8
68	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	8
67	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 563-569.e3	3.3	7
66	Postoperative radiation for prostate cancer. <i>Lancet, The</i> , 2012 , 380, 1974-6	4.0	7
65	POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. <i>Oncologist</i> , 2019 , 24, 1557-1561	5.7	7
64	Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. <i>Advances in Radiation Oncology</i> , 2017 , 2, 140-147	3.3	6
63	The current state of randomized clinical trial evidence for prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 599-610	2.8	6
62	The impact of MRE11 in nuclear to cytoplasmic ratio on outcomes in muscle invasive bladder cancer an analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 343-343	2.2	5
61	Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 276-276	2.2	5
60	Quantitative study of prostate cancer using three dimensional fiber tractography. <i>World Journal of Radiology</i> , 2016 , 8, 397-402	2.9	5

59	F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 997-1006	6.2	5
58	Words of wisdom. Re: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>European Urology</i> , 2015 , 67, 975	10.2	4
57	Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	4
56	Painting Dose: The ART of Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 722-728	4	4
55	Global Radiation Oncology From the Trainee Perspective: A View From Beyond the Bunker. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 438-9	4	4
54	Words of wisdom. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. <i>European Urology</i> , 2013 , 63, 181-2	10.2	4
53	INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 428-428	2.2	4
52	Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 ,	4	4
51	Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. <i>Transplantation Proceedings</i> , 2020 , 52, 2720-2725	1.1	3
50	Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2021 , 11, 675311	5.3	3
49	Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 362-368	3.3	3
48	Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. <i>Practical Radiation Oncology</i> , 2018 , 8, 206-212	2.8	2
47	Early salvage versus adjuvant post-prostatectomy radiation therapy: Long-term results of a large institutional experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 99-99	2.2	2
46	INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer SWOG/NRG1806.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS586-TPS586	2.2	2
45	Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 567-584	3.1	2
44	Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. <i>Bladder Cancer</i> , 2016 , 2, 203-213	1	2
43	Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 41-46.e1	3.3	2
42	Setting the stage for bladder preservation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 209-212	2.8	2

41	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , 2022 ,	10.2	2
40	Assessment of Proton Beam Therapy Use Among Patients With Newly Diagnosed Cancer in the US, 2004-2018.. <i>JAMA Network Open</i> , 2022 , 5, e229025	10.4	2
39	Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.. <i>JAMA Network Open</i> , 2022 , 5, e2211869	10.4	2
38	The Program for Enhanced Training in Cancer: An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. <i>JCO Global Oncology</i> , 2020 , 6, 13-13	3.7	1
37	Routine bladder cancer treatment dictates divergence from trial-derived regimens: Results of treatment at 44 radiotherapy centers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 9.e19-9.e25	2.8	1
36	Reply to Saeid Safiri and Erfan Ayubi Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>Eur Urol</i> 2017;71:952-60. Methodological Issues to Avoid Misinterpretation. <i>European Urology</i> , 2017 , 71, 1045-55	10.2	1
35	Response. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	1
34	Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 27-27	2.2	1
33	Exploring multidisciplinary practice patterns in the management of muscle invasive bladder cancer (MIBC) across the U.S. and Canada in 2015.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 368-368	2.2	1
32	Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 316-316	2.2	1
31	Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021 ,	6.7	1
30	Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. <i>Journal of Urology</i> , 2021 , 206, 29-36	2.5	1
29	Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer. <i>JAMA Surgery</i> , 2019 , 154, 184-185	5.4	1
28	Impact of Community-Based Clinical Breast Examinations in Botswana. <i>JCO Global Oncology</i> , 2021 , 7, 17-26	3.7	1
27	The impact of a positive family history on clinical and pathologic outcomes of active surveillance for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 225-225	2.2	1
26	Association of Race With Receipt of Proton Beam Therapy for Patients With Newly Diagnosed Cancer in the US, 2004-2018.. <i>JAMA Network Open</i> , 2022 , 5, e228970	10.4	1
25	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.. <i>European Urology</i> , 2022 ,	10.2	1
24	HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana.. <i>JCO Global Oncology</i> , 2022 , 8, e2100163	3.7	0

23	Editorial comment. <i>Urology</i> , 2019 , 124, 189-190	1.6
22	Treatment Trends for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 1976-7	27.4
21	Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1054-5	27.4
20	Radiotherapy use in the treatment of gastrointestinal cancers in Medicare patients: An analysis of a CMS database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 800-800	2.2
19	Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana. <i>JCO Global Oncology</i> , 2021 , 7, 1620-1632	3.7
18	Trends in the use of proton beam therapy among newly diagnosed cancer patients in the United States.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6551-6551	2.2
17	Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 941-948	7.3
16	An analysis of trends in prostate cancer treatment from a CMS database.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19288-e19288	2.2
15	Long-term outcomes after bladder-preserving combined-modality therapy for patients with muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 398-398	2.2
14	Renal function in bladder cancer patients after trimodality therapy: Long-term results of a large institutional experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 453-453	2.2
13	Re-irradiation of the pelvis for a genitourinary second malignant neoplasm or a local recurrence after full-dose pelvic radiotherapy for a pelvic cancer: Experience in a high-volume cancer center.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 494-494	2.2
12	Development and validation of contouring guidelines for post-cystectomy adjuvant radiation of bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 409-409	2.2
11	Risk factors for disease progression after post-prostatectomy salvage radiation: Long-term results of a large institutional experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 110-110	2.2
10	The prognostic utility of hemoglobin and lymphocytopenia in bladder-sparing therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 370-370	2.2
9	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9-9	2.2
8	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017 , 2017, 9-9	2.2
7	Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 287-287	2.2
6	TU-G-BRB-04: Optimal Frequency of CT Imaging for Monitoring Target Volume and Estimating Delivered Dose in Standard and Hypofractionated Prostate Proton Therapy. <i>Medical Physics</i> , 2011 , 38, 3779-3779	4.4

5	EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE) An ECOG-ACRIN and NRG Collaboration.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4590-TPS4590	2.2
4	Words of Wisdom. Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study. <i>European Urology</i> , 2016 , 69, 757-8	10.2
3	EDITORIAL COMMENT. <i>Urology</i> , 2019 , 133, 171-172	1.6
2	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy-Reply. <i>JAMA Oncology</i> , 2018 , 4, 1620-1621	13.4
1	Differences in Quality of Life Between Men and Women who Undergo Bladder Preservation with Trimodality Therapy. <i>Bladder Cancer</i> , 2021 , 7, 279-284	1